Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1803-1808

  Cavalieri, Elena ^a   Matturro, Angela ^a   Annechini, Giorgia ^a   De Angelis, Federico ^a   Frattarelli, Natalia ^a   Gentilini, Fabiana ^a   Grapulin, Lavinia ^b   Sacco, Mikael ^a   Torelli, Fabio ^a   Vignetti, Marco ^a   Mandelli, Franco ^a   Fo, Robin ^a   Pulsoni, Alessandro ^a  

^a Division of Hematology   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BEACOPP regimen; Hodgkin lymphoma; Refractory Hodgkin lymphoma; Relapsed Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; ASEPTIC NECROSIS; BLOOD TOXICITY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; LEUKEMIA; MALE; OVERALL SURVIVAL; PERICARDITIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPTIC SHOCK;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLOSIS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PERICARDITIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; PREDNISONE; PROCARBAZINE; RECURRENCE; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 71049143511     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903254383     Document Type: Article

References (19)

1. Diehl V, Franklin J, Pfreundschuh M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
2. Diehl V, Franklin J, Paulus U. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001;98:769-771.
3. Diehl V, Fuchs M; GHSG. Will BEACOPP be the standard for high-risk Hodgkin's lymphoma patients in advanced stages? Transfus Apher Sci 2007;37:37-41.
4. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143-148.
5. Engel C, Leffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose intensified BEACOPP chemotherapy for advanced stages Hodgkin's disease. GHSG. Ann Oncol 2000;11:1105-1114.
6. Lavoie JC, Connors JM, Philips GL, et al. High dose chemotherapy and autologous stem cell transplant for primary refractory or relapsed Hodgkin's lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473-1478.
7. Josting A. Autologous transplantation in relapsed and refractory Hodgkin's disease. Eur J Haematol 2005;66: 141-145.
8. Anselmo AP, Cavalieri E, Meloni G, et al. Dose intensifi- cation with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease. Haematologica 2002;87: 507-511.
9. Schmitz N, Pfistner B, Sextro M. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-2071.
10. Radman I, Basic N, Labar B, et al. Long term results of conventional dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002;13:1650-1655.
11. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339: 1506-1514.
12. Josting A, Rueffer U, Franklin J. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-1286.
13. Abdel hamid T, El Zawahry HM, Khattab NA, et al. Prognostic factors of Hodgkin's lymphoma and their impact on response to chemotherapy and survival. J Egypt Natl Canc Inst 2005;17:9-14.
14. Czyz J, Dziadziuszko R, Knopin'ska-Postuszuy W, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004;15:1222-1230.
15. Morabito F, Stelitano C, Luminari S, et al. The role of highdose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). BMT 2006;37:283-288.
16. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-123. (Pubitemid 40124488)
17. Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;3: 1-6.
18. Martínez C, Salamero O, Arenillas L, et al. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution. Leuk Lymphoma 2007;48:1968-1975.
19. Venkatesh H, Di Bella N, Flynn TP, et al. Results of a phase trial of single agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-115.